PMID- 11829279
OWN - NLM
STAT- MEDLINE
DCOM- 20020724
LR  - 20171116
IS  - 0890-9091 (Print)
IS  - 0890-9091 (Linking)
VI  - 16
IP  - 1 Suppl 1
DP  - 2002 Jan
TI  - DC2 effect on survival following allogeneic bone marrow transplantation.
PG  - 19-26
AB  - The graft-vs-tumor effect is an important part of the curative potential of 
      allogeneic transplantation. We characterized the effect of transplanted donor 
      mononuclear cells on relapse- and event-free survival after allogeneic bone 
      marrow transplantation (BMT). We studied 113 consecutive patients with 
      hematologic malignancies who received non-T-cell-depleted BMT from human 
      leukocyte antigen (HLA)-matched siblings. Most patients (n = 103) received 
      busulfan (Myleran)-based conditioning, and all patients received standard 
      short-course methotrexate and tacrolimus (Prograf) as graft-vs-host disease 
      prophylaxis. Sixty-four patients had low-risk diagnoses (acute lymphoblastic 
      leukemia/acute myeloid leukemia [first complete remission], myelodysplastic 
      syndrome [refractory anemia/refractory anemia with ring sideroblasts], and 
      chronic myeloid leukemia [first chronic phase]); 49 patients had high-risk 
      diagnoses (all others). Cox regression analyses evaluated risk strata, age, 
      gender, and the numbers of nucleated cells, CD3-positive T cells, CD34-positive 
      hematopoietic cells, and type 2 dendritic cells (DC2) as covariates for 
      event-free survival, relapse, and nonrelapse mortality. Recipients of larger 
      numbers of DC2 cells had significantly lower event-free survival, a lower 
      incidence of chronic graft-vs-host disease, and an increased incidence of 
      relapse. Recipients of larger numbers of CD34-positive cells had improved 
      event-free survival; recipients of fewer CD34-positive cells had delayed 
      hematopoietic engraftment and increased death from infections. In conclusion, 
      content of donor DC2 cells was associated with decreased chronic graft-vs-host 
      disease and graft-vs-leukemia effects consistent with Th2/Tc2 polarization of 
      donor Tcells following allogeneic bone marrow transplantation.
FAU - Waller, Edmund K
AU  - Waller EK
AD  - Bone Marrow and Stem Cell Transplant Center, Emory University, Atlanta, Georgia 
      30322, USA.
FAU - Rosenthal, Hilary
AU  - Rosenthal H
FAU - Sagar, Lonial
AU  - Sagar L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Oncology (Williston Park)
JT  - Oncology (Williston Park, N.Y.)
JID - 8712059
RN  - 0 (Antigens, CD34)
RN  - 0 (CD3 Complex)
SB  - IM
CIN - Oncology (Williston Park). 2002 Jan;16(1 Suppl 1):7-9. PMID: 11829282
MH  - Antigens, CD34/metabolism
MH  - *Bone Marrow Transplantation
MH  - CD3 Complex/metabolism
MH  - Dendritic Cells/*physiology
MH  - Graft vs Host Disease/immunology
MH  - Humans
MH  - Leukemia/immunology/*therapy
MH  - Survival Rate
MH  - T-Lymphocytes/immunology
MH  - Transplantation, Homologous
MH  - Treatment Outcome
RF  - 52
EDAT- 2002/02/07 10:00
MHDA- 2002/07/26 10:01
CRDT- 2002/02/07 10:00
PHST- 2002/02/07 10:00 [pubmed]
PHST- 2002/07/26 10:01 [medline]
PHST- 2002/02/07 10:00 [entrez]
AID - 162766 [pii]
PST - ppublish
SO  - Oncology (Williston Park). 2002 Jan;16(1 Suppl 1):19-26.